Periodontitis affects over half the global population, and severe cases rank among the world’s most common chronic conditions. Yet despite best-practice care, many patients see limited results.
Now, emerging science points to a new adjunctive approach: microbiome modulation.
This whitepaper presents new clinical findings on BLIS M18™, a targeted oral probiotic strain shown to improve key periodontal health indicators – probing pocket depth, bleeding on probing, and plaque index – when used alongside standard non-surgical treatment.
Global Key Account Manager ENQUIRE NOW
The study, published in 2025, demonstrates that BLIS M18™ not only improves short-term outcomes but sustains positive shifts in the oral microbiota long after supplementation ends. The probiotic also inhibits P. gingivalis—a primary pathogen in gum disease—and its virulence factors, offering a compelling new mechanism for managing oral inflammation at its root.
Whether you’re developing advanced oral health products or sourcing ingredients with proven efficacy, BLIS M18™ provides a precision solution backed by robust science.
